Disruptive technology revolutionizing drug delivery (Video)
Rapid Dose Therapeutics Corp. (CSE: DOSE) is a Canadian pharma-technology company that brings drug delivery solutions to a new level. RDT provides product innovation, production, and consultation to the pharmaceutical and healthcare manufacturing industry.
Hannah Bernard: Hi, I’m Hannah Bernard. You’re watching Market One Minute. Joining us today is Mark Upsdell of Rapid Dose Therapeutics. Mark, tell us what Rapid Dose Therapeutics is delivering to the market.
Mark Upsdell: At Rapid Dose Therapeutics, we’ve developed a game-changing, proprietary, disruptive technology. We have developed an oral thin film strip that works on a molecular level, revolutionizing the way that you would take many of the items found in your medicine cabinet, thus reducing the need to swallow pills and inject needles. RDT, Rapid Dose Therapeutics, has developed an oral thin film strip that works on a micronization of the molecules. We can embed almost any active ingredient into the strip.
Hannah Bernard: And it sounds very similar to the breath strip, can you expand on this?
Mark Upsdell: Unlike the breath strip, we can quickly deliver the active ingredients directly into the blood stream. This is a perfect fit for all ages. Over 40 per cent of the marketplace has a hard time swallowing pills. This will address a lot of the requirements for a lot of people across the globe.
Hannah Bernard: Can you explain how this technology can be applied to cannabis?
Mark Upsdell: So Rapid Dose Therapeutics, we work with our global cannabis partners. We provide a turn-key solution, which is very similar to the pay-per-use photocopier model. We allow and enable our partners to manufacture, sell, and distribute cannabis products. Their role in the service is to provide the labor, and they put the cannabis oil into the strip. We teach them, and we educate our partners how to infuse an oil-based product to make it water soluble.
Hannah Bernard: Very interesting, and now can you tell us about your recent global agreements?
Mark Upsdell: So, currently we have five five-year agreements, two with Aphria, one in Germany, one in Canada. Two with Chemeses, one in Puerto Rico, one is California, and most recently, Flower One in Nevada. These agreements will allow us to penetrate both the medical markets, and the recreational markets where it is legislated in each of those provinces, states, and countries.
Hannah Bernard: Can you elaborate on your agreement with Flower One?
Mark Upsdell: Recently we have signed an agreement with Flower One for Las Vegas. They are one of the largest cultivators in Nevada and we’re working with them to target both the recreational and the medical user for the area.
Hannah Bernard: And can you tell us what Rapid Dose Therapeutics is offering to investors?
Mark Upsdell: RDT for investors provides global scalable technology that is applicable across multiple verticals, such as the cannabis industry that we’re working on. We currently have 14 patents pending and continue with our R&D to support and work with some of the largest academic institutions across the globe.
Hannah Bernard: Thanks for sharing all that with us Mark.
Mark Upsdell: Thank you.